Company balance sheet At 31 December 2018 2018 2017 Note $m $m Non-current assets Property, plant and equipment 3 3 Intangible assets 48 23 20 Investments in subsidiaries 49 3,328 3,323 Due from subsidiaries 50 177 362 Financial and other non-current assets 1 5 3,532 3,713 Current assets Other receivables 5 3 Due from subsidiaries 50 41 71 Cash and cash equivalents 52 50 25 Other current assets 51 41 86 137 185 Total assets 3,669 3,898 Current liabilities Other payables 53 3 4 Due to subsidiaries 54 39 39 Other current liabilities 13 14 55 57 Net current assets 82 128 Non-current liabilities Long-term financial debts 55 500 610 Due to subsidiaries 54 77 115 577 725 Total liabilities 632 782 Net assets 3,037 3,116 Equity Share capital 57 40 40 Share premium 58 282 282 Other reserves 1,745 1,745 Retained earnings 59 970 1,049 Equity attributable to equity holders of the parent 3,037 3,116 The financial statements of Hikma Pharmaceuticals PLC, registered number 5557934, on pages 168 to 174 were approved by the Board of Directors on 12 March 2019 and signed on its behalf by: Said Darwazah Sigurdur Olafsson Director Director 12 March 2019 168 168 Hikma Pharmaceuticals PLC | Annual Report 2018 Financial statements Company statements of changes in equity For the year ended 31 December 2018 Share Share Own Merger Retained capital premium shares reserve earnings Total $m $m $m $m $m $m Balance at 1 January 2017 40 282 1 1,746 1,093 3,160 Profit for the year 12 12 Change in fair value of available-for-sale financial assets 1 1 Total comprehensive income for the year 13 13 Total transactions with owners, recognised directly in equity Cost of equity settled employee share scheme 22 22 Dividends paid 79 79 Balance at 31 December 2017 and 1 January 2018 40 282 1 1,746 1,049 3,116 Loss for the year 16 16 Total comprehensive income for the year 16 16 Total transactions with owners, recognised directly in equity Cost of equity settled employee share scheme 21 21 Dividends paid 84 84 Balance at 31 December 2018 40 282 1 1,746 970 3,037 1.
This investment was previously designated as available-for-sale financial assets.
Upon transition to IFRS 9 it has been re-categorised as Investments FVTPL Hikma Pharmaceuticals PLC | Annual Report 2018 169 169
